These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33643502)

  • 21. Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia.
    Harrison TS; Lyseng-Williamson KA
    BioDrugs; 2013 Feb; 27(1):69-74. PubMed ID: 23329395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
    Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
    Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
    Blum W; Phelps MA; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM; Johnson A; Schaaf LJ; Byrd JC; Marcucci G; Grever MR
    Haematologica; 2010 Jul; 95(7):1098-105. PubMed ID: 20460644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.
    Shah NN; Cole DE; Lester-McCully CM; Wayne AS; Warren KE; Widemann BC
    Invest New Drugs; 2016 Feb; 34(1):61-5. PubMed ID: 26661090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
    Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
    J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
    J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vincristine liposomal--INEX: lipid-encapsulated vincristine, onco TCS, transmembrane carrier system--vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI.
    Drugs R D; 2004; 5(2):119-23. PubMed ID: 15293876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
    Liedtke M; Twist CJ; Medeiros BC; Gotlib JR; Berube C; Bieber MM; Bhat NM; Teng NN; Coutre SE
    Haematologica; 2012 Jan; 97(1):30-7. PubMed ID: 21993685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
    Abou Dalle I; Cortes JE; Pinnamaneni P; Lamothe B; Diaz Duque A; Randhawa J; Pemmaraju N; Jabbour E; Ferrajoli A; Wierda WG; Estrov Z; Konopleva M; Ravandi F; Alvarado Y; Borthakur G; Gandhi V; Kantarjian HM
    Acta Haematol; 2018; 140(1):30-39. PubMed ID: 30071517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.
    Rodriguez MA; Pytlik R; Kozak T; Chhanabhai M; Gascoyne R; Lu B; Deitcher SR; Winter JN;
    Cancer; 2009 Aug; 115(15):3475-82. PubMed ID: 19536896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.